Kinase Domain Mutants of BCR Enhance BCR-Abl Oncogenic Effects

Oncogene - United Kingdom
doi 10.1038/sj.onc.1210851
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Protein Kinase CKIIa Interacts With the BCR Moiety of BCR/Abl and Mediates Proliferation of BCR/Abl-Expressing Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Kinase Domain Mutants of BCR-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2006English

Autoinhibition of BCR-Abl Through Its SH3 Domain

Molecular Cell
Cell BiologyMolecular Biology
2003English

Development of a Potent Protein Degrader Against Oncogenic BCR-ABL Protein

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
2019English

Bcr: A Negative Regulator of the BCR-Abl Oncoprotein in Leukemia

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Targeting the SH2-Kinase Interface in BCR-Abl Inhibits Leukemogenesis

Cell
BiochemistryGeneticsMolecular Biology
2011English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica
Hematology
2015English

An Amino-Acid Switch in the BCR-ABL Kinase Domain Modifies Sensitivity to Imatinib Mesylate

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy